'Leave medicines out of new NAFTA deals,' says AAM

The USA is actively negotiating with Mexico and Canada to revise the North American Free Trade Agreement (NAFTA).

One of the provisions under discussion would increase brand-name drug exclusivity (monopolies), says the generics trade group the Association for Accessible Medicines (AAM). Imposing additional brand-name drug exclusivity would keep already high brand drug prices out of reach for patients for longer.

Patients continue to pay skyrocketing brand drug prices as access to more affordable generics is delayed and the emerging biosimilars market in the USA is undermined, says the AAM.